Cargando…
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer
Histone deacetylase inhibitors (HDACs) are known to exhibit antiproliferative effects on various carcinoma cells. In this study, the in vivo efficiency of two HDACs, sodium butyrate and tributyrin, on prostate cancer growth inhibition were investigated. To gain an insight into the possible underlyin...
Autores principales: | Kuefer, R, Hofer, M D, Altug, V, Zorn, C, Genze, F, Kunzi-Rapp, K, Hautmann, R E, Gschwend, J E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409572/ https://www.ncbi.nlm.nih.gov/pubmed/14735205 http://dx.doi.org/10.1038/sj.bjc.6601510 |
Ejemplares similares
-
Tributyrin, a Butyrate Pro-Drug, Primes Satellite Cells for Differentiation by Altering the Epigenetic Landscape
por: Murray, Robert L., et al.
Publicado: (2021) -
Targeted PEGylated Chitosan Nano-complex for Delivery of Sodium
Butyrate to Prostate Cancer: An In Vitro Study
por: Zamanvaziri, Ali, et al.
Publicado: (2023) -
Lacticaseibacillus rhamnosus ATCC 53103 and Limosilactobacillus reuteri ATCC 53608 Synergistically Boost Butyrate Levels upon Tributyrin Administration Ex Vivo
por: Van den Abbeele, Pieter, et al.
Publicado: (2023) -
Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer
por: Kuefer, R, et al.
Publicado: (2005) -
Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007)